Home › Funds › Cercano Management LLC › DNLI
Cercano Management LLC position in DNLI
DENALI THERAPEUTICS INC · Health Care
Cercano Management LLC reported holding 625,000 shares of DNLI (DENALI THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$12.9M, representing 1.77% of its reported portfolio and ranking #7 among its reported holdings. Cercano Management LLC has disclosed DNLI holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Cercano Management LLC's DNLI position evolved
Cercano Management LLC first disclosed a stake in DNLI in Q3 2023 at 625,000 shares (US$12.9M). The position peaked in Q3 2024 at 625,000 shares, worth US$18.2M. Across 13 filings, Cercano Management LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 625,000 shares valued at US$12.9M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 625.00K | $12.89M | New |
| Q4 2023 | 625.00K | $13.41M | Hold |
| Q1 2024 | 625.00K | $12.82M | Hold |
| Q2 2024 | 625.00K | $14.51M | Hold |
| Q3 2024 | 625.00K | $18.21M | Hold |
| Q4 2024 | 625.00K | $12.74M | Hold |
| Q1 2025 | 625.00K | $8.50M | Hold |
| Q2 2025 | 625.00K | $8.74M | Hold |
| Q3 2025 | 625.00K | $9.07M | Hold |
| Q4 2025 | 625.00K | $10.32M | Hold |
| Q1 2026 | 625.00K | $12.00M | Hold |
| Q2 2026 | 625.00K | $16.07M | Hold |
| Q3 2026 | 625.00K | $12.92M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DNLI and 13F data
DNLI (DENALI THERAPEUTICS INC) is a Health Care company. 40 other funds we track also report a position in DNLI — the largest reported positions include Temasek Holdings (US$180.4M), Temasek Holdings (Private) Ltd (US$145.0M), BAKER BROS. ADVISORS LP (US$96.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DNLI
- Temasek Holdings 7.01M sh · $180.37M · Q2 2026
- Temasek Holdings (Private) Ltd 7.01M sh · $144.96M · Q3 2026
- BAKER BROS. ADVISORS LP 3.73M sh · $96.05M · Q2 2026
- Casdin Capital 2.04M sh · $52.60M · Q2 2026
- Crestline Management, L.P. 1.91M sh · $49.14M · Q2 2026
- Foresite Capital Management VI LLC 1.40M sh · $35.92M · Q2 2026
- Siren, L.L.C. 1.40M sh · $28.87M · Q3 2026
- ADAR1 Capital Management, LLC 1.03M sh · $26.47M · Q2 2026
More on Cercano Management LLC
FAQ
How long has Cercano Management LLC held DNLI?
Cercano Management LLC has disclosed DNLI holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Cercano Management LLC's current position in DNLI?
As of Q3 2026, Cercano Management LLC holds 625.00K shares of DNLI (DENALI THERAPEUTICS INC), valued at $12.92M, representing 1.77% of its reported portfolio and ranking #7.
Has Cercano Management LLC been buying or selling DNLI?
In the latest 13F filing (Q3 2026), Cercano Management LLC held unchanged its position in DNLI. The position peaked in Q3 2024 at 625.00K shares.
Which other funds hold DNLI?
Other major institutional holders of DNLI include Temasek Holdings, Temasek Holdings (Private) Ltd, BAKER BROS. ADVISORS LP, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.